Section Review Central & Peripheral Nervous Systems: New anti-epileptic drugs

References

• MATTSON RH, CRAMER JA, COLLINS JF, DEPARTMENT OFVETERANS AFFAIRS EPILEPSY COOPERATIVE STUDY NO. 264 GROUP: A comparison of valproate with car-bamazepine for the treatment of complex partial sei-zures and secondarily generalized tonic-clonic seizures in adults. New Engl. J. Med. (1992) 327:765–771
   Google Scholar
• HELLER AJ, CHESTERMAN P, ELWES RD, CRAWFORD P,CHADWICK D, JOHNSON AL, REYNOLDS EH: Phenobar-bitone, phenytoin, carbamazepine, or sodium vat proate for newly diagnosed adult epilepsy: a randomised comparative monotherapy triaL J. Neurol. Neurosurg. Psychiatry (1995) 58(1):44–50.
   PubMed Web of Science ®Google Scholar
• DEVINSKY O: Cognitive and behavioral effects of anti-epileptic drugs. Epilepsia (1995) 36\(Suppl. 2):S46–S65.
   Google Scholar
• SUTULA TP, CAVAZOS JE, WOODARD AR: Long-term structural and functional alterations induced in thehippocampus by kindling: implications for memory dysfunction and development of epilepsy. Hippocampus (1994) 4(3):254–258.
   PubMed Web of Science ®Google Scholar
• SCHMUTZ M, ICLEBS K, BALTZER V: Inhibition or en-hancement of kindling evolution by anti-epileptics. J. Neural Transm. 16enJ (1988) 72:245–257.
   PubMedGoogle Scholar
• SILVER JM, SHIN C, MCNAMARA JO: Anti-epikptogenic effects of conventional aunti-convulsants in the kindling model of epilepsy. Ann. Neurol. (1991) 29:356–363.
   PubMedGoogle Scholar
• MELDRUM BS: The role of glutamate in epilepsy and other CNS disorders. Neurology (1994) 44\(Suppl. 8):514–S23.
   Google Scholar
• SUZDAK PD, JANSEN JA: A review of the preclinicalpharmacology of tiagabine: A potent and selective anti-convulsant GABA uptake inhibitor. Epilepsia (1995) 36(6):612–626.
   PubMed Web of Science ®Google Scholar
• CRUNELLI V, LERESCHE N: A role for GABAB receptors inexcitation and inhibition of thalamocortical cells. TINS (1991) 14:16–21.
   PubMed Web of Science ®Google Scholar
• LEPPIK IE: Felbamate. Epilepsia (1995) 36\(Suppl. 2):S66–S72.
   Google Scholar
• RHO JM, DONEVAN SD, ROGAWSKI MA: Mechanism of action of the anti-convulsant felbamate: opposing effect on N-methyl-D-aspartate and gamma-aminobutyric acid A receptors. Ann. Neurol. (1994) 35:229–234.
   PubMed Web of Science ®Google Scholar
• WHITE HS, WOLF HH, SWINYARD EA, SKEEN GA, SOFIARD: A neuropharmacological evaluation of felbamate as a novel anti-convulsant. Epilepsia (1992) 33:564–572.
   PubMed Web of Science ®Google Scholar
• CHRONOPOULOS A, STAFSTROM C, THURBER S, HYDE P, MIKATI M, HOLMES GL: Neuroprotective effect of fel-bamate after kainic add-induced status epilepticus. Eptlepsia (1993) 43:693–696.
   Google Scholar
• WALLIS RA, PANIZZON ICL, NOLAN JP: Glycine-induced CA1 excitotoxicity in the rat hippocampal slice. Brain Res. (1994) 664(1–2)115–125.
   Google Scholar
• WASTERLEIN CG, ADAMS LM, HATTORI H, SCHWARTZ PH:Felbamate reduces hypoxic-ischemic brain damage in vivo. Eur. J. Pharmacol. (1992) 212:275–278.
   PubMedGoogle Scholar
• PENNELL PB, OGAILY MS, MACDONALD RL: Aplastic ane-mia in a patient receiving felbamate for complex partial seizures. Neurology (1995) 45(3):456–460.
   PubMed Web of Science ®Google Scholar
• MATTSON RH: Efficacy and adverse effects of established and new anti-epileptic drugs. Epilepsia (1995) 36\(Suppl. 2):S13–S26.
   Google Scholar
• TAYLOR CP: Emerging perspectives on the mechanismof action of gabapentin. Neurology (1994) 44\(Suppl. 5):S10–S16.
   Google Scholar
• ANDREWS CO, FISCHER JH: Gabapentin: a new agent forthe management of epilepsy. Ann. Pbarmacother. (1994) 28(10):1188–1196.
   PubMed Web of Science ®Google Scholar
• GOA KL, SORKIN EM: Gabapentin: a review of its phar-macological properties and clinical potential in epi-lepsy. Drugs (1993) 46:409–427.
   PubMed Web of Science ®Google Scholar
• DODRELL CB, WILENSKY AJ, OJEMANN LM: Neuropsy-chological, mood, and psychosocial effects of gabap-entin. Epilepsia (1992) 33\(Suppl. 3):S117–S118.
   Google Scholar
• FISCHER JH, BARR AN, ROGERS SL, FISCHER PA, TRUDEAU VL: Lack of serious toxicity following gabapentin over-dose. Neurology (1994) 44:982–983.
   PubMed Web of Science ®Google Scholar
• LEES G, LEACH MJ: Studies on the mechanism of action of the novel anti-convulsant lamotrigine using primary neuroglial cultures from rat cortex. Brain Res. (1993) 34:190–199.
   Google Scholar
• O'DONNELL RA, MILLER AA: The effect of lamotrigine upon development of cortical kindled seizures in the rat. Neuropharmacology (1991) 30:253–258.
   PubMed Web of Science ®Google Scholar
• MCGEER EG, ZHU SG: lamotrigine protects against kai-nate but not ibotenate lesions in rat striatum. Neurosci. Lett. (1990) 4(112)348–351.
   Google Scholar
• SMITH SE, MELDRUM BS: Cerebroprotective effect oflamotrigine after focal ischemia in rats. Stroke (1995) 26:117–122.
   PubMed Web of Science ®Google Scholar
• MESSENHEIMER JA: Lamotrigine. Epilepsia (1995) 36\(Suppl. 2):S87–594.
   Google Scholar
• BETTS T: Communication of pooled results of 27 open studies of lamotrigine as add-on therapy for up to 12 months in adults with treatment resistant epilepsy. J. Neurology (1990) 237\(Suppl. 1):S52.
   Google Scholar
• BRODIE MJ, RICHENS A, YUEN AWC: Double-blind com-parison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet (1995) 25(345):476–479.
   Google Scholar
• STEINER TJ, SILVEIRA C, YUEN AWC: Comparison of lamotrigine and phenytoin monotherapy in newly di-agnosed epilepsy. Epilepsia (1994) 35\(Suppl. 7):S61.
   Google Scholar
• WARNER T, PATSALOS PN, PREVE1-1 M: Lamotrigine-in-duced carbamazepine toxicity: an interaction with carba m7f-pine-10,11-epoxide.Epilepsy Res. (1992)11:147–150.
   PubMed Web of Science ®Google Scholar
• BINNIE CD: Lamotrigine. Epilepsia (1995) 36\(Suppl. 3):532.
   Google Scholar
• GRANT S, FAULDS D: Oxcarbazepine, A review of its pharmacology and therapeutic potential in epilepsy, trigerninal neuralgia and affective disorders. Drugs (1992) 43(0:873–888.
   PubMedGoogle Scholar
• MCLEAN MJ, SCHMUTZ M, WAMIL AM: Oxcarbazepine: Mechanisms of action. Epilepsia (1994) 35\(Suppl. 3):S5–59.
   Google Scholar
• ALMA M, KÄLVIA.INEN R, SIVENIUS J, HALONEN T, RIEK-KINEN PJ: Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res. (1992) 11:199–203.
   PubMed Web of Science ®Google Scholar
• PATSALOS PN, DUNCAN JS: New anti-epileptic drugs, A review of their current status and clinical potential. CNS Drugs (1994) 2(1):40–77.
   Web of Science ®Google Scholar
• BROWN P, STEIGER MJ, THOMPSON PD: Effectiveness of piracetam in cortical myoclonus. Moe. Disord. (1993) 8:63–68.
   PubMed Web of Science ®Google Scholar
• CHALTDRY FIR, NAJAM N, DE MAHIEU C: Clinical use ofpiracetam in epileptic patients. Curr. 7'her. Res. (1992) 52:355–360.
   Web of Science ®Google Scholar
• GRANT SM, HEEL RC: Vigahatrin. A review of its pharma-codynamic and pharmacokinetic properties and thera-peutic potential in epilepsy and disorders of motor control Drugs (1991) 41:889–926.
   Google Scholar
• KALVIAINEN R, HALONEN T, PITKANEN A, RIEKKINEN PJ:Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies. I Neurochem. (1993) 60:1244–1250.
   PubMed Web of Science ®Google Scholar
• PETROFF OAC, ROTHMAN DL, BEHAR KL, MATTSON RH:Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of garnma-aminobutyric acid, glutamate and glutamine in human brain. Epilepsia (1995) 36(5):457–464.
   PubMed Web of Science ®Google Scholar
• SHIN C, RIGSBEE LC, MCNAMARA JO: Anti-seizure andanti-epileptogenic effect of garnma-vinyl-gamma-ami-nobutyric acid in amygdaloid kindling. Brain Res. (1986) 398:370–374.
   PubMed Web of Science ®Google Scholar
• PITKANEN A, HALONEN T: Prevention of neuronal cell damage in the temporal lobe by vigabatrin and car-bamazepine in experimental status epikpticus. Epilep-sia (1994) 35\(Suppl. 8):S64.
   Google Scholar
• YLINEN AMA, MIETTINEN R, PITKANEN A, GULYAS Al, FREUND T, RIEKKINEN PJ: Enhanced GABAergic inhibi-tion preserves hippocampal structure and function in a model of epilepsy. Proc. Natl. Acad. Sci. USA (1991) 88:7650–7653.
   PubMed Web of Science ®Google Scholar
• KALVIAINEN R, AIKIA M, MERVAALA E, SAUKKONEN AM, RIEKKINENVigabatrin v& carbamazepine mono-therapy in newly diagnosed patients with epilepsy. A randomized, controlled study. Arch. Neurol. (1995). In press.
   Google Scholar
• DODRILL CB, AR= JL, SOMMERVILLE KW, SUSSMANNM: Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy_ Neurology (1993) 43:2501–2507.
   Google Scholar
• DODRILL CB, ARNETT JL, SOMMERVILLE KW, SUSSMANNM: Effects of differing dosages of vigabatrin on cogni-tive abilities and quality of life in epilepsy. Epilepsia (1995) 36(2):164–173.
   PubMedGoogle Scholar
• GIBSON JP, YARRINGTON TT, LOUDY DE, GERBIG CG,HURST GH, NEWBERNE JW: Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol. Pathol. (1990) 18:225–238.
   PubMed Web of Science ®Google Scholar
• CANNON DJ, BUTLER WH, MUMFORD JP, LEWIS PJ: Neuropathological findings in patients receiving long-term vigabatrin therapy for chronic intractable epi-lepsy. J. Child Neurol. (1991) 6:17–24.
   Google Scholar
• JACKSON GD, GRUNEWALD RA, CONNELLY A, DUNCANJS: Quantitative MR relaxometry study of the effects of vigabatrin on the brains of patients with epilepsy. Epilepsy Res. (1994) 18(2):127–137.
   PubMed Web of Science ®Google Scholar
• HAMODA K, ISHIDA S, YAGI K: Anti-convulsant effectsof zonisamide on amygdalokl kindling in rats. Neurosci. (1990) 16:407–412.
   Google Scholar
• LEPPIK 1E, WILLMORE LJ, HOMAN RW: Efficacy and safetyof zonisamide: results of a multicenter study. Epilepsy Res. (1993) 14:165–173.
   PubMed Web of Science ®Google Scholar
• SCHMIDT D, JACOB R, LOISEAU P: Zonisamide for add-on treatment of refractory partial epilepsy: a critical as-sessment. Epilepsy Res. (1993) 15:67–73.
   PubMed Web of Science ®Google Scholar
• HENRY TR, LEPPIK IE, GUMNIT RJ, JACOBS M: Progressive myoclonus epilepsy treated with zonisamide. Neurology (1988) 38:928–931.
   PubMed Web of Science ®Google Scholar
• PETERS DH, SORKIN EM: A review of its pharmacody-namic and pharmacokinetic properties and therapeu-tic potential in epilepsy. Drugs (1993) 45:760–787,
   PubMed Web of Science ®Google Scholar
• GOWER AJ, NOYER M, VERLOES R: UCB L059, a novel anti-convuLsant: pharmacological profile in animals. Eur. J. Pharmacol. (1992) 222:193–203.
   PubMed Web of Science ®Google Scholar
• WALKER MC, SHARIEF MK, SANDER JWAS, PATSALOS PN, SHORVON SD: Early experience with UC,B L059 in refractory epilepsy. Epilepsia (1994) 35\(Suppl. 7):S76.
   Google Scholar
• NEYENS LGJ, ALPHERTS WCJ, ALDENKAMP AP: Cognitive side-effects of levetiracetam. Epilepsia (1994) 35 (Suppl. 7):S76.
   Google Scholar
• STEIN U, KLESSING K, CHAI IERJEE SS: Losigamone. Epi-lepsy Res. (1991) 3:129–133.
   Google Scholar
• MORRIS GL, COLLINS S, BELL W, SAHLROOT T, CEREGH-INO J, DIENEL A: Losigamone in partial seizures. Epilepsia (1994) 35\(Suppl. 8):S114.
   Google Scholar
• BANNAN PE, GRAHAM DI, LEES KR, MCCULLOCH J: Neuro-protective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res. (1994) 664(12):271–275.
   PubMedGoogle Scholar
• ORDY JM, THOMAS GJ: Remacemkk effects on memory and hippocampal CA1 neuronal damage in the rat four-vessel occlusion model of global cerebral is-chemia. Soc. Neurosci. Abstr. (1991) 17:1081.
   Google Scholar
• CHADWICK DW, SMITH D, BAKER G, CRAWFORD P, ANDERSON E, HARRISON B, JAMIESON V: Retnacemide hydrochloride safety, tolerability and pharmacokinet-ics. Epilepsia (1994) 35\(Suppl. 7):S61.
   Google Scholar
• VINCENT JC: Stiripentol. Epilepsy Res. (1991) 3:153–156.
   Google Scholar
• MENGEL H: Tiagabine. Epilepsia (1994) 35\(Suppl. 5):S81–S84.
   Google Scholar
• LASSEN LC, SOMMERVILLE K, MENGEL HB, EDWARDS D, NIELSEN B, SHIT V: Summary of five controlled trials with tiagabine as adjunctive treatment of patients with partial seizures. Epilepsia (1995) 36\(Suppl. 3):S148.
   Google Scholar
• SCHACHTER S, WANNAMAKER B, CAHILL W, SACHDEO R, FIEASELL M, SHU V, HIGHTOWER B, SOMMERVILLE K: Dose-ranging study to determine the tolerability of tiagabine HCL adminstered as monotherapy. Epilepsia (1995) 36\(Suppl. 3):S148
   Google Scholar
• KALVIAINEN R, AIKIA M, MERVAALA E, RIEKKINEN P: Long-term cognitive effects of tiagabine. Epilepsia (1995) 36\(Suppl. 3):S149.
   Google Scholar
• DODRILL CB, ARNETT JL, SOMMERVILLE K, MENGEL fI: Tiagabine. Epilepsia (1995) 36(Suppl 3):S31.
   Google Scholar
• BROWN SD, WOLF HH, SWINYARD EA, TWYMAN RE, WHITE HS: The novel anti-convulsant topiramate en-hances GABA-mediated chloride flux. Epilepsia (1993) 34\(Suppl. 2):5122.
   Google Scholar
• Topiramate: New advances in the treatment of epilepsy. Clinical Courier (1995) 13(6):1–8.
   Google Scholar
• DICHTER MA: Emerging insights into mechanisms ofepilepsy: Implications for new anti-epileptic drug de-velopment. Epilepsia (1994) 35\(Suppl. 4):S51–S57.
   Google Scholar